Rochelle Bagatell, MD
Areas of expertise: Neuroblastoma (high risk, relapsed, and refractory), Neuroblastoma (non-high risk), Sarcomas, Solid tumors
Locations: Main Building
About Rochelle Bagatell, MD
Rochelle Bagatell, MD, is a pediatric oncologist with expertise in the care of children with solid tumors. She has a particular interest in the treatment of patients with neuroblastoma and sarcomas, and is the solid tumor section chief at The Children's Hospital of Philadelphia.
Current treatment regimens are effective for many children diagnosed with solid tumors in childhood, and the collaborative approach taken at Children's Hospital allows patients to benefit from the expertise of surgeons, pathologists, radiologists, radiation oncologists, nurses, nutritionists and other specialists who work together to provide state-of-the-art care for patients. The solid tumor team is committed to optimizing the effectiveness of current therapies while trying to minimize the side effects of treatment.
This group is also committed to developing new treatments for childhood solid tumors. As a member of Children's Hospital’s oncology developmental therapeutics team, Dr. Bagatell is involved in research studies (clinical trials) of new agents for patients whose cancers don't respond to initial or established treatments. She and colleagues conduct research trials that provide patients access to the newest anticancer medications. The team studies novel treatments that haven't previously been administered to children. These trials permit better understanding of how to use new treatments in the most effective way. The team is currently expanding the number of new agent trials available to patients, and collaborates with colleagues from around the region and nation in efforts to advance the field.
While there are tremendous challenges inherent in the pursuit of new treatments, the solid tumor and developmental therapeutics teams have the opportunity to build upon the expertise at Children’s Hospital to develop newer, less toxic treatments for childhood cancer. Dr. Bagatell’s highest priority is to make innovative treatments available to the children who need them.
Titles
Attending Physician
Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Certifications
Pediatric Hematology-Oncology – American Board of Pediatrics
Pediatrics – American Board of Pediatrics
Awards and Honors
2022, Philadelphia Magazine's Top Doctors in Pediatric Hematology-Oncology
2006-2015, Best Doctors in America
2006, Alpha Omega Alpha
2002, Vernon and Virginia Furrow Award for Excellence in Clinical Science Teaching
2001, University Animal Care Outstanding Investigator Award, University of Arizona
2000, Children’s Oncology Group Young Investigator Award
2000, University of Arizona, College of Medicine, Dean’s Physician Scientist Career Development Award
1999, Pharmacia-Upjohn Outstanding Fellow Award, Arizona Cancer Center, Tucson AZ
1996, Resident of the Year, Pima County Pediatric Society, Tucson AZ
1996, Resident Teacher of the Year Award, Department of Pediatrics, University of Arizona
1993, Hugh Thompson Award, Outstanding Medical Student in Pediatrics
1989-1993, Dean’s Scholar, University of Arizona
1987, Phi Beta Kappa
Leadership and Memberships
2010-present, Solid Tumor Section Chief, Division of Oncology, The Children's Hospital of Philadelphia
2011-present, Vice Chair, Children’s Oncology Group Neuroblastoma Committee
Editorial and Academic Positions
Editorial Positions
Editorial Board, Journal of Clinical Oncology
Research Interests
Clinical trials Neuroblastoma
Education & training
Medical Degree
MD - University of Arizona, Tucson, AZ
Internship
Pediatrics - University of Arizona, Tucson, AZ
Residency
Pediatrics - University of Arizona, Tucson, AZ
Fellowship
Pediatric Hematology/Oncology - Children's Memorial Hospital, Northwestern University, Chicago, IL
Pediatric Hematology/Oncology - University of Arizona, Tucson, AZ
Publications
Publications
2016
DiNofia AM, Salazar E, Seif AE, Li Y, Huang, YS, Bagatell R, Fisher BT, Aplenc R. Bortezomib Inpatient Prescribing Practices in Free-Standing Children’s Hospitals in the United States. PLoS One. March 2016: e0151362 PMID 26978062.
Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can Be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated with Recurrence. Pediatric Blood and Cancer, Epub ahead of print Feb 2016. PMID: 26864375
Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing RB, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PA, Aplenc R. Accuracy of Adverse Event Ascertainment on Clinical Trials for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, Epub ahead of print Feb 2016. PMID: 26884588
DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. Phase 1 Study of the Aurora A Kinase Inhibitor Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial. Journal of Clinical Oncology Epub ahead of print, Feb 2016. PMID: 26884555
Desai AV, Seif AE, Li Y, Getz, Fisher BT, Huang YS, Mante A, Aplenc R, Bagatell R. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. Pediatric Blood and Cancer. 63(5):901-7, 2016. PMID: 26797923
Bagatell R, McHugh K, Naranjo A, Van Ryn C, Kirby C, Brock P, Lyons KA, States LJ, Rojas Y, Miller A, Volchenboum SL, Simon T, Krug B, Sarnacki S, Valteau-Couanet D, von Schweinitz D, Kammer B, Granata C, Pio L, Park JR, Nuchtern J. Assessment of Primary Site Response in Children with High-Risk Neuroblastoma: An International Multi-Center Study. Journal of Clinical Oncology. 34(7): 740-6, 2016. PMID: 26755515
Bagatell R, McHugh K, Naranjo A, Van Ryn C, Kirby C, Brock P, Lyons KA, States LJ, Rojas Y, Miller A, Volchenboum SL, Simon T, Krug B, Sarnacki S, Valteau-Couanet D, von Schweinitz D, Kammer B, Granata C, Pio L, Park JR, Nuchtern J. Assessment of Primary Site Response in Children with High-Risk Neuroblastoma: An International Multi-Center Study. Journal of Clinical Oncology. 34(7): 740-6, 2016. PMID: 26755515
2015
Li Y, Hall M, Fisher BT, Seif AE, Huang YS, Bagatell R, Getz KD, Alonzo TA, Gerbing RB, Sung L, Adamson PC, Gamis A, Aplenc R. Merging Children’s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children’s Oncology Group. PLoS One. 10 (11): e0143480, 2015. PMID: 26606521
Lee GE, Fisher BT, Xiao R, Coffin SE, Feemster K, Seif AE, Bagatell R, Li Y, Huang YS, Aplenc R. Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia. J Pediatr Infect Dis Soc. 4(4): 290-6, 2015. PMID: 26582867
Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Bagatell R, Fisher BT, Aplenc R. A Comparison of Resource Utilization Following Chemotherapy for Acute Myeloid Leukemia in Children Discharged Versus Children That Remained Hospitalized During Neutropenia. Cancer Medicine. 4(9): 1356-64, 2015. PMID: 26105201
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R. Comparison of Inpatient Costs for Children Treated on the AAML0531 Clinical Trial: A Report from the Children’s Oncology Group. Pediatric Blood and Cancer. 62(10): 1775-81, 2015. PMID: 25946708
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R. Comparison of Inpatient Costs for Children Treated on the AAML0531 Clinical Trial: A Report from the Children’s Oncology Group. Pediatric Blood and Cancer. 2015 May 6. doi: 10.1002/pbc.25569. [Epub ahead of print]
Miller TP, Troxel AB, Li Y, Huang Y-S, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R. Comparison of Administrative/Billing Data to Expected Protocol-Mandated Chemotherapy Exposure in Children with Acute Myeloid Leukemia: A Report from the Children’s Oncology Group. Pediatric Blood and Cancer. 2015 Mar 11. doi: 10.1002/pbc.25475. [Epub ahead of print]
Lectures by Invitation
2015
Bagatell R. A View from the Bedside: Pediatric Sarcomas in Perspective. University of Pennsylvania Sarcoma Retreat; 2015 Dec 12; Philadelphia PA.
Bagatell R. Multidisciplinary Care of Children with Solid Tumors” Continuing Medical Education Series for Primary Care Providers; 2015 May 19; Bridgewater NJ.
Bagatell R. Targeted Therapy Comes of Age for the Treatment of High-Risk Neuroblastoma. Oncology Research Conference, Texas Children’s Hospital, Baylor College of Medicine; 2015 Mar; Houston TX.
2014
Bagatell R. The Long and Winding Road Toward Development of New Drugs for Childhood Cancer. Pediatric Grand Rounds, Sinai Hospital; 2014 Oct; Baltimore MD.